Boehringer Ingelheim and CDR-Life Sign Global Licensing Agreement for CDR111, a Trispecific Antibody for Autoimmune Diseases
Wednesday, November 05, 2025
Boehringer Ingelheim and CDR-Life Inc. have entered into a global licensing agreement to develop CDR111, a trispecific antibody-based molecule designed for the treatment of autoimmune diseases. CDR111, known as an M-gager®, is a T-cell engager that selectively targets and depletes B cells, aiming to reset the immune system and restore balance.
B cells are known to play a major role in driving several autoimmune and inflammatory conditions such as lupus, multiple sclerosis, and certain types of arthritis. A treatment approach that can effectively deplete these cells has the potential to offer significant therapeutic benefits across multiple disease areas.
This agreement extends the existing collaboration between the two companies, which previously focused on developing an investigational antibody fragment aimed at preserving vision in patients with geographic atrophy (GA). The molecule, developed using CDR-Life’s licensed technology, is currently under evaluation in Boehringer’s VERDANT™ Phase 2 clinical trial (NCT06722157).
The partnership aims to build on this progress by applying CDR-Life’s trispecific M-gager® technology to autoimmune and inflammatory diseases with high unmet medical need. Boehringer Ingelheim will advance the development of CDR111 through clinical evaluation and further expansion of its immunology pipeline.
Under the terms of the agreement, CDR-Life will receive up to CHF 456 million (approximately USD 570 million) in total payments, including CHF 38 million (around USD 48 million) in upfront and near-term payments, along with tiered royalties on future product sales.
Source: globenewswire.com
